Julie Yoo is a computer scientist turned healthcare operator-investor who co-founded Kyruus and served as its Chief Product Officer before becoming a VC, giving her hands-on experience with provider scheduling, referrals, and operational workflows that she calls "living the plumbing" of healthcare systems. She champions healthcare fintech as its own investment category, arguing that following money flows like claims and payments is the most leveraged way to fix healthcare incentives, and she actively looks for companies that rebuild core routing infrastructure rather than just adding interfaces on top of legacy systems.

• Deep interest in AI as a fundamental structural shift rather than just a productivity tool. She frequently discusses how AI acts as a new site of care that allows the industry to leapfrog legacy infrastructure, similar to how mobile finance in Kenya bypassed traditional banking systems. She specifically looks for AI-native companies that avoid skeuomorphic designs, meaning she wants startups creating entirely new care models rather than just digitizing a traditional doctor's visit.
• A focus on business model innovation and novel reimbursement strategies. She actively tracks how the market pays for new technologies, highlighting the rise of Challenger Health Plans that are disrupting commercial insurance. She views the consumer as a major new payer class with significant influence over the market, noting that out-of-pocket spend is driving the unbundling of generalist tools like ChatGPT into specialized healthcare use cases.
• Appreciation for technical depth and the complex plumbing of healthcare data. As a former engineer who describes herself as a recovering Perl pirate, she values technical rigor and standardization. She often points out the need for better data infrastructure, joking about the need for a Unicode Consortium for CPT codes and highlighting the importance of startups fixing backend issues like Medicaid eligibility and dated government infrastructure.
• Emphasis on the operational realities of building a company, particularly the necessity of sales and distribution. Drawing on her own past experience as a co-founder, she warns that first-time founders often underestimate the importance of sales. She categorizes startups into Challengers versus Enablers to differentiate between those competing directly with incumbents and those selling tools to them, suggesting founders should be clear on which path they are taking.
• Interest in redefining patient engagement metrics. She challenges the traditional view that frequent interaction with the healthcare system is a negative sign, proposing that modern healthtech should move beyond just serving sick patients. She uses specific frameworks to describe this shift, contrasting the historical model of Sick Monthly Active Users with the need to cultivate engagement among healthy individuals who previously only interacted with the system once a year.